An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women - PubMed (original) (raw)
Clinical Trial
An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women
S M Garland et al. Int J STD AIDS. 2006 Jul.
Abstract
Our objective was to determine the optimal duration of treatment with imiquimod for external genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts for a median of 3-6 months and prior alternative treatments in 73% were evaluated for total clearance rates. There was no statistically significant difference in complete clearance rates after 16-week follow-up across treatment groups: four weeks (40.0%), eight weeks (48.4%), 12 weeks (39.3%) and 16 weeks (51.6%). Imiquimod was well tolerated, and in those treated for four weeks there was a lower incidence of local skin reactions such as erythema and erosion, and no incidences of pain. These preliminary results suggest that a four-week treatment course of imiquimod applied thrice weekly for women with external genital warts may provide a reasonable approach with comparable efficacy and compliance, and minimal adverse events, drug costs and clinic visits.
Similar articles
- Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
Fife KH, Ferenczy A, Douglas JM Jr, Brown DR, Smith M, Owens ML; HPV Study Group. Fife KH, et al. Sex Transm Dis. 2001 Apr;28(4):226-31. doi: 10.1097/00007435-200104000-00007. Sex Transm Dis. 2001. PMID: 11318254 Clinical Trial. - Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA. Edwards L, et al. Arch Dermatol. 1998 Jan;134(1):25-30. doi: 10.1001/archderm.134.1.25. Arch Dermatol. 1998. PMID: 9449906 Clinical Trial. - Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations.
Sauder DN, Skinner RB, Fox TL, Owens ML. Sauder DN, et al. Sex Transm Dis. 2003 Feb;30(2):124-8. doi: 10.1097/00007435-200302000-00006. Sex Transm Dis. 2003. PMID: 12567169 Clinical Trial. - Topical imiquimod: a review of its use in genital warts.
Perry CM, Lamb HM. Perry CM, et al. Drugs. 1999 Aug;58(2):375-90. doi: 10.2165/00003495-199958020-00017. Drugs. 1999. PMID: 10473026 Review. - Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.
Schöfer H. Schöfer H. Br J Dermatol. 2007 Dec;157 Suppl 2:52-5. doi: 10.1111/j.1365-2133.2007.08274.x. Br J Dermatol. 2007. PMID: 18067633 Review.
Cited by
- Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.
Pacheco-García U, Varela-López E, Serafín-López J. Pacheco-García U, et al. Int J Mol Sci. 2024 Jul 12;25(14):7661. doi: 10.3390/ijms25147661. Int J Mol Sci. 2024. PMID: 39062904 Free PMC article. Review. - [Anogenital warts-An update].
Chromy D, Silling S, Wieland U, Kreuter A. Chromy D, et al. Dermatologie (Heidelb). 2024 Jan;75(1):30-39. doi: 10.1007/s00105-023-05282-8. Epub 2023 Dec 18. Dermatologie (Heidelb). 2024. PMID: 38108864 Review. German. - Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R, Nugent D, Bennett K, Doré CJ, Murray ML, Meadows J, Haddow LJ, Lacey C, Sandmann F, Jit M, Soldan K, Tetlow M, Caverly E, Nathan M, Copas AJ. Gilson R, et al. Health Technol Assess. 2020 Sep;24(47):1-86. doi: 10.3310/hta24470. Health Technol Assess. 2020. PMID: 32975189 Free PMC article. Clinical Trial. - Position statement for the diagnosis and management of anogenital warts.
O'Mahony C, Gomberg M, Skerlev M, Alraddadi A, de Las Heras-Alonso ME, Majewski S, Nicolaidou E, Serdaroğlu S, Kutlubay Z, Tawara M, Stary A, Al Hammadi A, Cusini M. O'Mahony C, et al. J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1006-1019. doi: 10.1111/jdv.15570. Epub 2019 Apr 10. J Eur Acad Dermatol Venereol. 2019. PMID: 30968980 Free PMC article. - Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
Murray ML, Meadows J, Doré CJ, Copas AJ, Haddow LJ, Lacey C, Jit M, Soldan K, Bennett K, Tetlow M, Nathan M, Gilson R. Murray ML, et al. BMC Med Res Methodol. 2018 Nov 6;18(1):125. doi: 10.1186/s12874-018-0581-z. BMC Med Res Methodol. 2018. PMID: 30400777 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical